Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.
Press releases published on July 9, 2025
Dr. Anosh Ahmed Plans $25,000 Donation to Support FBI Families and Law Enforcement Mental Health Programs
GlobeNewswire
·
July 9, 2025
Image by Dr. Anosh Ahmed CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed, a Chicago-based physician and founder of the Anosh Inc Foundation, has announced plans to donate $25,000 to nonprofit organizations that support FBI agents and their …
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
GlobeNewswire
·
July 9, 2025
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 ( …
Medical Supplierz Expands as Global B2B Marketplace for Medical Equipment Trade
EIN Presswire
·
July 9, 2025
KUWAIT, KUWAIT, July 9, 2025 /EINPresswire.com/ -- Medical Supplierz, a digital B2B platform designed specifically for the medical sector, is gaining rapid traction as a trusted online space for global suppliers and healthcare buyers. With increased …
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
GlobeNewswire
·
July 9, 2025
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire
·
July 9, 2025
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 ( …
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
GlobeNewswire
·
July 9, 2025
CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
GlobeNewswire
·
July 9, 2025
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …
FluidForm Bio™ Presents Six-Month Efficacy Data of FRESH 3D Bioprinted Human Islet Subcutaneous Scaffolds at the American Diabetes Association (ADA) 85th Scientific Sessions
GlobeNewswire
·
July 9, 2025
WALTHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced two presentations at recent medical meetings: the 20th World Congress of the International Pancreas …
TerrAscend Completes $79 Million Non-Dilutive Debt Financing
GlobeNewswire
·
July 9, 2025
Proceeds used to retire $68 million of existing debt with the remainder designated for future growth initiatives Additional facility of up to $35 million available for strategic M…
Amneal to Report Second Quarter 2025 Results on August 5, 2025
GlobeNewswire
·
July 9, 2025
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial results on …
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
GlobeNewswire
·
July 9, 2025
NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension …
CoRegen, Inc. Closes More Than $93 Million Financing
GlobeNewswire
·
July 9, 2025
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced the close of a $93,390,000 million financing. The proceeds …
Benitec Biopharma Provides Operational Updates
GlobeNewswire
·
July 9, 2025
-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects …
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
GlobeNewswire
·
July 9, 2025
KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation …
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
GlobeNewswire
·
July 9, 2025
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its …
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
GlobeNewswire
·
July 9, 2025
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-lasting …
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
GlobeNewswire
·
July 9, 2025
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reductions in bivamelagon trial were consistent with BMI …
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
GlobeNewswire
·
July 9, 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, …
Atsena Therapeutics Announces Alignment with FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)
GlobeNewswire
·
July 9, 2025
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential …
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
GlobeNewswire
·
July 9, 2025
[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a study No treatment limited toxicities observed Patient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, …